Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer

RADES, DIRK; KRISTIANSEN, CHARLOTTE; TIMKE, CARMEN; DUMA, MARCIANA N.; YU, NATHAN Y.; BARTSCHT, TOBIAS; JANSSEN, STEFAN

doi:10.21873/anticanres.16949

Cited by 3 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A considerable number of patients irradiated for breast cancer develop more severe dermatitis of grade ≥2, which may impair the patient's quality of life (11). In two recent studies of our group investigating patients irradiated for breast cancer, the prevalence of grade ≥2 radiation dermatitis was 25.3% and 31.2%, respectively (1,12). In addition, we identified independent risk factors for developing grade ≥2 dermatitis, which included age ≤60 years, chronic inflammatory disease, significant cardiovascular disease, smoking history >10 packyears, advanced primary tumor stage, normo-fractionation of radiotherapy, and administration of a radiation boost.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Seasonal Impact on Grade ≥2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis

RADES,

JANSSEN,

NARVAEZ-WOLF

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

Background/Aim: We investigated grade ≥2 dermatitis in patients irradiated for breast cancer. This study evaluated associations between dermatitis and the season during which radiotherapy took place. Patients and Methods: Associations between the season and grade ≥2 dermatitis were retrospectively evaluated in 327 breast cancer patients. Seasons were March to May (spring), June to August (summer), September to November (autumn), and December to February (winter). Subgroup analyses were performed considering fractionation, radiation technique, treatment volume, radiation boost, and deep-inspiration breath-hold technique. Furthermore, warmer and cooler months were compared. Results: The season had no significant impact on the rate of grade ≥2 dermatitis in the entire cohort (p=0.63) nor in the subgroup analyses (pvalues between 0.17 and 0.82). No significant difference in rate was found between warm and cool months. Conclusion: Grade ≥2 dermatitis was not associated with the season during which radiotherapy was performed. This factor may not be important for stratification in prospective trials.Recently, we investigated the prevalence and risk factors of grade ≥2 radiation dermatitis in patients irradiated for invasive breast cancer following breast-conserving surgery or mastectomy (1). In this additional study, it was evaluated whether the season or the average temperature of the period during which radiotherapy took place have a significant impact on the rate of grade ≥2 radiation dermatitis. The hypothesis tested was that grade ≥2 dermatitis occurs more often during the summer or during warmer months. Increased toxicity during the summer season was previously found in patients receiving adjuvant chemotherapy for breast cancer and patients receiving 5fluorouracil for colorectal cancer (2, 3). Moreover, in a survey regarding acute radiation-induced dermatitis that was completed by health professionals from Radiation Oncology departments in German-speaking countries, more than 90% of the participants recommended avoidance of hot baths and exposure to the sun as risk-reducing measures (4). If the current study shows that the season or the average temperature have a significant impact on the prevalence of grade ≥2 radiation dermatitis, these aspects should be considered when designing future prospective trials.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The characteristics of these patients have been previously described (1). In the current study, associations between the season during which the patients were irradiated and grade ≥2 radiation-associated dermatitis were evaluated.…”

mentioning

confidence: 99%

Seasonal Impact on Grade ≥2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis

RADES,

JANSSEN,

NARVAEZ-WOLF

et al. 2024

Anticancer Res

View full text Add to dashboard Cite

show abstract

Associations between breast radiation dermatitis and post-mastectomy pain syndrome in patients with breast cancer: A multicenter retrospective study

Ren,

Gao,

Zhang

et al. 2024

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Dermatitis during adjuvant irradiation for breast cancer (DAI-BREAC): A randomized trial investigating whether grade ≥2 dermatitis during radiotherapy for breast cancer can be reduced by a mobile application that reminds patients to perform skin care

Rades,

Narvaez-Wolf,

Dziggel

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Radiotherapy of breast cancer can be associated with dermatitis. Grade ≥ 2 radiation dermatitis can be painful and impair the patients’ quality of life. To reduce the risk of this complication, patients have to perform skin care several times each day. This may require a considerable level of compliance. This randomized DAI-BREAC trial investigates whether a mobile application reminding the patients four times per day to perform skin care (reminder app) will contribute to reduction of grade ≥ 2 radiation dermatitis. Methods This multinational, randomized, active-controlled, parallel-group, multicenter trial compares standard skin care supported by a reminder app (Arm A) versus standard skin care alone (Arm B) regarding grade ≥ 2 radiation dermatitis in patients receiving adjuvant radiotherapy for breast cancer. The effect of the app will be considered clinically relevant, if the rate of grade ≥ 2 radiation dermatitis is reduced from 25.4% (rate identified in a preceding study) to 15%. A total of 134 patients per arm including drop-outs are required. Secondary aims include pain (visual analogue scale), patient satisfaction with the app (questionnaire), impact of the app on the use of health technology (questionnaire), and benefit from support (coaching) by staff members regarding the use of the app (questionnaire). Discussion If reminder app contributes to a decrease of grade ≥ 2 radiation dermatitis in patients irradiated for breast cancer, it will likely become a useful instrument for these patients. Trial registration: clinicaltrials.gov (NCT06483477; URL: https://clinicaltrials.gov/show/NCT06483477). Registered on 1st of July, 2024. First patient is planned to be included in September 2024.

show abstract

Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer

Cited by 3 publications

References 20 publications

Seasonal Impact on Grade ≥2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis

Seasonal Impact on Grade ≥2 Dermatitis in Patients With Breast Cancer Undergoing Radiotherapy: A Supplementary Analysis

Associations between breast radiation dermatitis and post-mastectomy pain syndrome in patients with breast cancer: A multicenter retrospective study

Dermatitis during adjuvant irradiation for breast cancer (DAI-BREAC): A randomized trial investigating whether grade ≥2 dermatitis during radiotherapy for breast cancer can be reduced by a mobile application that reminds patients to perform skin care

Contact Info

Product

Resources

About